Navigation Links
EntreMed Receives Nasdaq Deficiency Notice
Date:4/4/2008

itate investment in the Company by a broader group of institutional investors. As a result, there may be less volatility in the Company's stock price, which would enable the Company to raise funds at a lower cost to finance its ongoing research, product development, and clinical trials, and to meet other business objectives unrelated to NASDAQ listing rules.

EntreMed, Inc., President and CEO, James S. Burns, commented on the notification, "Micro-cap biotech companies, including ours, have experienced substantial downward pressure on stock prices. Our stock price has fallen in line with other oncology companies at our stage of development, a situation that I strongly believe is due to market weakness rather than any fundamentals within EntreMed specifically. We are committed to bringing the Company back into compliance, investing behind our most promising programs, managing our cash conservatively, and meeting our milestones."

Mr. Burns continued, "The deficiency notification does not immediately affect our NASDAQ listing, nor does it impact our 2008 plan to invest behind our most promising programs. Our pipeline has a sharper focus and we are devoting increased time and resources to partnering one or several of our programs. Our goal is to continue improving the quality of our pipeline, de-risk the Company, and build shareholder value."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and comm
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
2. EntreMed Announces 2008 Corporate and Clinical Program Priorities
3. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
4. EntreMed to Present at BIO CEO and Investor Conference
5. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
6. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
7. EntreMed Appoints Senior Vice President of Research and Development
8. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
9. Memory Pharmaceuticals Receives Nasdaq Notification
10. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
11. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3
Breaking Biology News(10 mins):New science estimates carbon storage potential of US lands 2UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of Washington professor garners Avanti Young Investigator Award 2Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 1Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 2Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 3Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 1Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 2Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 3Cleaning Up Indoor Air Quality 3A New Certification Standard for Cleaning Products Will Help Millions of People Make More Educated Choices 61585 1Cleaning Up Indoor Air Quality 3A New Certification Standard for Cleaning Products Will Help Millions of People Make More Educated Choices 61585 2Cleaning Up Indoor Air Quality 3A New Certification Standard for Cleaning Products Will Help Millions of People Make More Educated Choices 61585 3